Moleculin Completes Enrollment in Part A of Pivotal MIRACLE Trial; Q1 2027 Data Readout on Track
MBRX has more than doubled off its 52-week low of $0.161.
Summary
Enrollment in Part A of the pivotal MIRACLE trial has been completed with 89 subjects, keeping the Q1 2027 data readout on track. The final dataset is expected to be roughly 50/50 fit vs unfit patients, a shift from the 70/30 split in the first 45 subjects.
Key Events · Product Development and Regulatory · MBRX
-
Part A Enrollment Completed
Enrollment in Part A of the pivotal Phase 2/3 MIRACLE trial has closed with 89 subjects enrolled and two additional subjects in screening.
-
Q1 2027 Data Readout on Track
The company remains on track for its planned comprehensive Part A data readout in the first quarter of 2027.
-
Patient Composition Shift
The final Part A dataset is expected to approximate a 50/50 split between fit and unfit subjects, versus roughly 70/30 in the first 45 subjects — a more challenging cohort for treatment responses.
-
No Cardiotoxicity Observed
Blinded MIRACLE data continues to show an absence of cardiotoxicity, differentiating Annamycin from conventional anthracyclines.
Analysis · MBRX · Life Sciences
Enrollment in Part A of the pivotal Phase 2/3 MIRACLE trial has closed with 89 subjects, keeping the comprehensive data readout on track for Q1 2027. This milestone matters because it moves the company closer to a binary clinical outcome that could define Annamycin's path toward approval in relapsed/refractory AML. The shift in patient composition toward a roughly 50/50 fit/unfit split — versus 70/30 in the first 45 subjects — is a double-edged signal: it broadens the dataset's relevance across distinct AML populations but also introduces a more challenging cohort for achieving treatment responses. Against the backdrop of going-concern doubts and a Nasdaq delisting notice, this operational execution is a positive but does not remove the financing risk the company itself flags.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.9% of the 1656 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MBRX was trading at $0.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.6M. The 52-week trading range was $0.16 to $15.75. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.